- Novartis donates 27,000 units of hand sanitizer to support New York’s response to the COVID-19 public health emergency
- Donation builds on Novartis efforts in the US for communities impacted by the pandemic, including funding and in-kind donations
- In line with Novartis global initiatives to respond to the pandemic, including a Global Response Fund, product donations, and industry-wide R&D collaboration
Long Island, New York, June 15, 2020 – Novartis, through its Long Island Operations site known as Fougera, today announces the donation of 27,000 units of hand sanitizer to support New York’s response to the COVID-19 public health emergency. As part of the larger Novartis COVID-19 Community Response Fund, the Novartis US Foundation has established a Fund and mechanism to support local efforts such as this.
Long Island Operations began manufacturing hand sanitizer at the Hicksville site to help with the pandemic as well as for internal Novartis use in the U.S. The hand sanitizer donation will support statewide first responders including hospitals, state agencies, nursing homes, nonprofit organizations and others.
“It is the first time we have manufactured hand sanitizer. With the hard work and dedication of all of the associates, we quickly put all of the pieces in place to make this happen,” said James Apollo, Director Operations, Site Head. “Our associates are the heroes, and I am exceptionally proud of the work that was done. They remain engaged and dedicated to support not just our patients, customers, co-workers, and company, but also the community where we work and live.”
To apply to the Novartis US COVID-19 Community Response Fund, please visit https://www.novartis.us/coronavirus.
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 145 nationalities work at Novartis around the world. Find out more at https://www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews
For Novartis multimedia content, please visit https://www.novartis.com/news/media-library
For questions about the site or required registration, please contact [email protected].
# # #
Novartis Media Relations
E-mail: [email protected]
|Head, US Corp & Country External Comms||Director, US Media Relations*|
|Global Media & Corp Communications||+1 862 217 3976|
|+1 646 438 4335||[email protected]|
|Chris Lewis||Leslie Pott|
|Sandoz Global Communications||Sandoz US Communications|
|+49 174 244 9501 (mobile)||+1 201 354 0279 (mobile)|
|[email protected]||[email protected]|